What is Spirair?
Spirair is a medical technology company co-founded by two Stanford Biodesign and Innovation fellows. The company is dedicated to addressing the unmet need for minimally invasive solutions within the Ear, Nose, and Throat (ENT) field. Spirair aims to enhance patient care by optimizing outcomes and improving the patient experience. Their pioneering solutions are designed for seamless integration into existing ENT treatment algorithms, enabling healthcare providers to assist a larger patient base in breathing better.
How much funding has Spirair raised?
Spirair has raised a total of $12.8M across 1 funding round:
Private Equity
$12.8M
Private Equity (2025): $12.8M, investors not publicly disclosed
What's next for Spirair?
The recent major enterprise-level funding and strategic investment indicate Spirair is poised for significant scaling and market penetration. This capital infusion will likely fuel further research and development, expand manufacturing capabilities, and support broader commercialization efforts. Spirair's focus on integrating innovative, minimally invasive solutions into ENT practices suggests a strategic push to become a leader in improving respiratory care and patient outcomes globally.
See full Spirair company page
